Neoadjuvant paclitaxel for operable breast cancer: Multicenter phase II trial with clinical outcomes

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1239-1244

  Kimura, Morihiko ^a   Sano, Muneaki ^b   Fujimori, Minoru ^c   Nakagomi, Hiroshi ^d   Negishi, Takeshi ^e   Yanagita, Yasuhiro ^f   Sato, Nobuaki ^g  

^a Ota Memorial Hospital   (Japan)

^b Niigata Breast Exam Center   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Yamanashi Prefectural Central Hospital   (Japan)

^e National Hospital Organization   (Japan)

^f Gunma Cancer Center   (Japan)

^g NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

Breast cancer; HER2 overexpression; Neoadjuvant chemotherapy; Paclitaxel

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; ESTROGEN RECEPTOR; FAMOTIDINE; PACLITAXEL; RANITIDINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BREAST CANCER; CANCER PAIN; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; GENE OVEREXPRESSION; GRANULOCYTOPENIA; HEARTBURN; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; ONCOGENE NEU; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 42549111541     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wolmark N, Wang J, Mamounas E, Bryant J and Fisher B: Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monographs 30: 96-102, 2001.
2. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19: 4224-4237, 2001.
3. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL and Wolmark N: Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
4. Kimura M, Koida T and Yanagita Y: Weekly administration of paclitaxel for advanced or metastatic breast cancer short-course premedications for outpatients. Jpn J Cancer Chemother 27: 1703-1708, 2000.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
6. The Japanese Breast Cancer Society edited: General Rules for Clinical and Pathological Recording of Breast Cancer" (in Guidelines for Treatment of Breast Cancer, 13th Edition; edited by the Japanese Breast Cancer Society. KANEHARA&CO., LTD. 1998.
7. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol 9(Suppl 3): 1-82, 2004.
8. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F and Hortobagyi GN: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 11: 3412-3417, 1999.
9. Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buyse M and Pouillart P: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22: 4958-4965, 2004.
10. Bauerfeind G, Nestle-Kraemling C, Kahlert S, Muck B, Bastert G, Wagner U, Bothmann G, Brumm C, Schulz K-D and Untch M: Surgical management of patients following preoperative chemotherapy for primary breast cancer; results from a prospective randomised AGO protocol with dose dense paclitaxel and epirubicin chemotherapy [abstract 84]. Proc Am Soc Clin Oncol 22, 2003.
11. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P and Bonadonna G: European Cooperative Trial in Operable Breast Cancer Study Group.: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Res 11: 8715-8721, 2005.
12. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W and Hortobagyi GN: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23: 5983-5992, 2005.
13. Norton L and Simon R: The Norton-Simon Hypothesis Revisited. Cancer Treat Reports 70: 163-169, 1986.
14. Norton L: Evolving Concepts in the Systemic Drug Therapy of Breast Cancer. Semin Oncol 24: S10-3-S10-10, 1997.
15. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J and Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
16. Perez EA, Vogel CL, Irwin DH, Kirshner JJ and Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223, 2001.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 344: 783-792, 2001.
18. Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
19. Merlin JL, Barberi-Heyob M and Bachmann N: In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines. Ann Oncol 13: 1743-1748, 2002.
20. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D and Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
23. BA Gusterson, RD Gelber, A Goldhirsch, KN Price, J Save-Soderborgh, R Anbazhagan, J Styles, CM Rudenstam, R Golouh and R Reed: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992.
24. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR and Flom KJ: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
25. Piccart MJ, Di Leo A and Hamilton A: HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 36: 1755-1761, 2000.
26. Lohrisch C and Piccart M: HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2: 129-135, 2001.
27. Piccart M, Lohrisch C, Di Leo A and Larsimont D: The predictive value of HER2 in breast cancer. Oncology 61(S2): 73-82, 2001.